Novelos Therapeutics
Madison · Founded 1996
About Novelos Therapeutics
Novelos Therapeutics, (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company's compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company's second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.
Company Facts
- Founded: 1996
- Legal name: Novelos Therapeutics, Inc.,
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $85.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2014)
- Website: novelos.com
- Phone: +1 6179646331
Canonical: https://fsome.com/organization/novelos-therapeutics-8449273 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.